

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

ANNOUNCEMENT ON THE COMMENCEMENT OF THE FIRST EXERCISE PERIOD UNDER THE FIRST GRANT

References are made to the announcements of the Company dated 30 August 2022, 21 September 2022, 7 November 2022, 23 November 2022 and 18 December 2023 and the circular of the Company dated 27 September 2022 (the “**Circular**”) in relation to, among others, the proposed adoption of the Incentive Scheme and/or the First Grant. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Circular.

The Date of Grant of the Share Options under the First Grant was 7 November 2022, the date of completion of the grant registration was 23 November 2022, and the first vesting period under the First Grant expired on 22 November 2023.

On 18 December 2023, the Board considered that the Exercise Conditions for the first exercise period under the First Grant have been fulfilled, and agreed that 1,001 Incentive Participants who meet the Exercise Conditions would be entitled to exercise 7,045,000 Share Options during the first exercise period, with the Exercise Price of RMB31.31/A Share.

On 26 December 2023, after verification by Shenzhen Stock Exchange and Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. (“**SDC**”), the Share Options of the first exercise period under the First Grant will be exercisable from 2 January 2024. The abbreviation of the exercisable Share Options is Livzon JLC3 and the code of the Share Options is 037312.

The exercise period of Share Options of the first exercise period under the First Grant is from 2 January 2024 to 22 November 2024. The Exercise Date must be a trading date, as such, the last trading date of this exercisable period shall be 22 November 2024.

The Incentive Participants must exercise during the exercise period, the granted but outstanding Share Options shall not be exercised after the expiry of the exercise period.

GF Securities Co., Ltd. (“**GF Securities**”) is responsible for the management of this exercise of the Share Options. To the best knowledge of the Board, GF Securities has taken measures to ensure that the functions of its business system comply with the compliance requirements and has completed the relevant preparation to satisfy the requirements for exercising the Share Options at the discretion of the Incentive Participants as imposed by SDC.

GF Securities guarantees that its business system can control and prevent exercising the Share Options and short-term trading of the Shares by the Incentive Participants during the price-sensitive period. Prior to the commencement of the exercising of the Share Options at the discretion of the Incentive Participants, the Company, GF Securities and the Incentive Participants have received the relevant trainings, which enable them to understand the compliance requirements for exercising the Share Options, and the relevant business control measures adopted by GF Securities are considered effective by the Board for the abovementioned reasons.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
26 December 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*